학술논문

Safety and Efficacy of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN) Based Treatment (Tx) Failure